is a serious eye infection caused by several types of bacteria. Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. Herbal medicines are also being developed for better treatment measures. This report encompasses analysis of the global market for bacterial conjunctivitis treatment on the basis of treatment methods, infection type, antibacterial class and geography.
The bacterial conjunctivitis treatment market is classified on the basis of methods into:
The prescription and usage of the aforementioned medications depends on severity of infection and even the cause. Advancements in research on microbiology have been supporting the pharmaceutical companies to develop and launch various anti-bacterial drugs that are useful for effective treatment of bacterial conjunctivitis.
North America leads the market with a share of XX% followed by APAC. APAC is set to be the fastest growing market for the coming years, growing at a CAGR of XX%. Introduction of new formulations and increasing reach of healthcare are the major drivers in APAC region. China and India provides huge growth opportunities for the market players. The key players in the bacterial conjunctivitis treatment market include:
- Akorn, Inc.
- Pfizer, Inc.
- Merck & Co.
- Novartis AG
- Bayer AG
The estimates and forecasts have been derived based on various inputs from primary and secondary sources. Secondary sources such as articles, whitepapers, journals and other has helped to deliver an extensive analysis in this report. To enhance the accuracy of the estimates, the data has been validated by conducting interviews with industry experts. This report on the bacterial conjunctivitis treatment market identifies many such insights, market share analysis and innovation, besides providing a detailed analysis of the key players, distributors and growth rate of the market.